Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not

Pancreatic neuroendocrine tumours (pan-NETs) are neoplasms arising from the endocrine cells of the pancreas. Although pan-NET are quite rare, the incidence is on the rise and together with other abdominal neuroendocrine tumours an approximate incidence in Sweden would be 850 patients per year extrapolating from Norwegian data. Pan-NET are divided into symptomatic hormone producing tumours (such as insulinomas/glucagonomas/VIPomas) or non-functioning tumours that often are asymptomatic. As early symptoms often are lacking in non-functioning-pan-NET, many patients present with distant metastases

Trial Details

NCT ID
NCT07273409
Phase
NA
Sponsor
Uppsala University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Debulking surgery
Locations (sample)
  • Gothenburg, Sweden|57.70716,11.96679
  • Lund, Sweden|55.70584,13.19321
  • Stockholm, Sweden|59.32938,18.06871
  • Uppsala, Sweden|59.85882,17.63889

Key Eligibility Criteria

  • Pan- NET, ENETS/AJCC stage 4 determined by CT or PET/CT
  • Primary tumour or metastases confirmed as Pancreatic NET GI-WHO grade 1-2 pan-NET by histology or cytology
  • Age ≥ 18 years
  • Written informed consent obtained

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →